Figure S2 shows representative stainings of (+), (++) or (+++) AKT1 expression in SCCs and ADCs. Tumours were classified into a low expression group comprising (−) and (+) and a high expression group that comprises (++) and (+++). Analysis of TMAs 258.1 and 258.2 showed that AKT1 was over-expressed in 17/96 NSCLC cases (∼19%) (Figure 2), with SCCs and ADCs showing similar results: 7/37 AKT1 positive tumors were SCCs (19%) and 7/44 AKT1 positive tumours were ADCs (16%). See Figure 2A and B, respectively. Nine out of 15 (60%) NSCLCs overexpressing AKT1 showed AKT activation (Table 3). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.